Inhibition of interleukin 2 by serum in healthy individuals and in patients with autoimmune disease

Int Arch Allergy Appl Immunol. 1987;84(2):135-41. doi: 10.1159/000234412.

Abstract

To study the mechanisms that regulate the activity of interleukin 2 (IL 2) and possibly limit its activity, we have examined normal human serum for its ability to inhibit IL 2-mediated proliferation of a cloned IL 2-dependent cytotoxic T lymphocyte line (CTLL). Normal human serum contains a factor capable of inhibiting IL 2 dependent proliferation of CTLL cells. This factor is absorbed with the cells but not IL 2 molecules. The inhibitor is heat-labile and inactivated by trypsin treatment. The molecular weight of the inhibitor is 70,000-220,000. The imbalance of the inhibitor is observed in serum from patients with autoimmune disease including systemic lupus erythematosus and rheumatoid arthritis. These results suggest that the serum IL 2 inhibitor may play an important role in the in vivo regulatory mechanism of IL 2 activity and in aberrant immune functions in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arthritis, Rheumatoid / blood*
  • Autoimmune Diseases / blood*
  • Humans
  • Interleukin-2 / antagonists & inhibitors*
  • Lupus Erythematosus, Systemic / blood*
  • Lymphocyte Activation / drug effects
  • Lymphokines / blood*
  • Lymphokines / pharmacology
  • Molecular Weight
  • T-Lymphocytes, Cytotoxic / drug effects

Substances

  • Interleukin-2
  • Lymphokines
  • interleukin 2 inhibitor